These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 15078)

  • 1. Synthesis and pharmacological properties of a series of antidopaminergic piperidyl benzamides.
    Prieto J; Moragues J; Spickett RG; Vega A; Colombo M; Salazar W; Roberts DJ
    J Pharm Pharmacol; 1977 Mar; 29(3):147-52. PubMed ID: 15078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and neuroleptic activity of benzamides. Cis-N-(1-benzyl-2-methylpyrrolidin-3-yl)-5-chloro-2-methoxy-4-(methylamino)benzamide and related compounds.
    Iwanami S; Takashima M; Hirata Y; Hasegawa O; Usuda S
    J Med Chem; 1981 Oct; 24(10):1224-30. PubMed ID: 6120234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and central dopaminergic effects of N-(4,6-dimethyl-2-pyridinyl)benzamides.
    Bouhayat S; Piessard S; Le Baut G; Sparfel L; Petit JY; Piriou F; Welin L
    J Med Chem; 1985 May; 28(5):555-9. PubMed ID: 4039368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Antagonism of pre- and postsynaptic dopamine receptors by clebopride and related orthopramides].
    Berga P; Beckett PR; Roberts DJ
    Arch Farmacol Toxicol; 1979 Dec; 5(3):144-6. PubMed ID: 546329
    [No Abstract]   [Full Text] [Related]  

  • 5. Behavioral pharmacology of the benzamides as compared to standard neuroleptics.
    Worms P
    Adv Biochem Psychopharmacol; 1982; 35():7-16. PubMed ID: 6128876
    [No Abstract]   [Full Text] [Related]  

  • 6. [Clebopride, a new orthopramide with potent and selective central antidopaminergic properties].
    Roberts DJ; Salazar W; Beckett PR; Nahorski SR
    Arch Farmacol Toxicol; 1978 Apr; 4(1):102-4. PubMed ID: 100059
    [No Abstract]   [Full Text] [Related]  

  • 7. Novel benzamides as selective and potent gastrokinetic agents. 2. Synthesis and structure-activity relationships of 4-amino-5-chloro-2-ethoxy-N-[[4-(4-fluorobenzyl)-2- morpholinyl]methyl] benzamide citrate (AS-4370) and related compounds.
    Kato S; Morie T; Kon T; Yoshida N; Karasawa T; Matsumoto J
    J Med Chem; 1991 Feb; 34(2):616-24. PubMed ID: 1995885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Selective antidopaminergic properties of remoxiprid, a new potential antipsychotic agent].
    Ogren SO; Hall H; Köhler C; Magnusson O; Florvall L
    Arzneimittelforschung; 1985; 35(8):1227-31. PubMed ID: 2866774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The benzamides: evidence for action at dopamine receptors--shortcomings of current models.
    Wazer DE; Rotrosen J; Stanley M
    Adv Biochem Psychopharmacol; 1982; 35():83-95. PubMed ID: 6756063
    [No Abstract]   [Full Text] [Related]  

  • 10. Potential neuroleptic agents. 2,6-Dialkoxybenzamide derivatives with potent dopamine receptor blocking activities.
    Florvall L; Ogren SO
    J Med Chem; 1982 Nov; 25(11):1280-6. PubMed ID: 6128419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and biological activity of picobenzide (3,5-dimethyl-N-(pyridin-4-ylmethyl)benzamide) analogues as potential antipsychotic agents.
    Gradillas A; López B; Braña MF; Sancho I; Pérez-García C; Alguacil LF
    Arzneimittelforschung; 2005; 55(12):725-9. PubMed ID: 16430025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A critical assessment of behavioural test procedures used to analyse dopaminergic and antidopaminergic drugs.
    Nohria V
    Methods Find Exp Clin Pharmacol; 1983; 5(6):357-64. PubMed ID: 6137599
    [No Abstract]   [Full Text] [Related]  

  • 13. A central site of action for benzamide facilitation of gastric emptying.
    Costall B; Gunning SJ; Naylor RJ; Simpson KH
    Eur J Pharmacol; 1983 Jul; 91(2-3):197-205. PubMed ID: 6617741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological and biochemical studies on a new potential neuroleptic, N-(1-benzyl-3-pyrrolidinyl)-5-chloro-2-methoxy-4-methylaminobenzamide (YM-08050).
    Usuda S; Sano K; Maeno H
    Arch Int Pharmacodyn Ther; 1979 Sep; 241(1):68-78. PubMed ID: 43118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Substituted benzamides with conformationally restricted side chains. 2. Indolizidine derivatives as central dopamine receptor antagonists.
    King FD; Hadley MS; McClelland CM
    J Med Chem; 1988 Sep; 31(9):1708-12. PubMed ID: 2900897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antipsychotic properties of new N-(4-substituted-1-piperazinylethyl)- and N-(4-substituted-1-piperidinylethyl)-phthalimides.
    al-Rashood KA; Mustafa AA; Alhaider AA; Ginawi OT; Madani AA; el-Obeid HA
    J Pharm Sci; 1988 Oct; 77(10):898-901. PubMed ID: 2907047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparison of antiapomorphinic activity of metoclopramide, sulpiride and clebopride in the rat and dog].
    Salazar W; Colombo M; Llupia J; Roberts DJ
    Arch Farmacol Toxicol; 1978 Apr; 4(1):60-3. PubMed ID: 697404
    [No Abstract]   [Full Text] [Related]  

  • 18. Effects of buspirone on dopamine dependent behaviours in rats.
    Dhavalshankh AG; Jadhav SA; Gaikwad RV; Gaonkar RK; Thorat VM; Balsara JJ
    Indian J Physiol Pharmacol; 2007; 51(4):375-86. PubMed ID: 18476392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Substituted benzamides as cerebral dopamine antagonists in rodents.
    Elliott PN; Jenner P; Huizing G; Marsden CD; Miller R
    Neuropharmacology; 1977 May; 16(5):333-42. PubMed ID: 559256
    [No Abstract]   [Full Text] [Related]  

  • 20. The nucleus amygdaloideus centralis and neuroleptic activity in the rat.
    Costall B; Naylor RJ
    Eur J Pharmacol; 1974 Feb; 25(2):138-46. PubMed ID: 4154850
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.